Xlife Sciences’ portfolio company VERAXA Biotech AG, a biopharmaceutical company focused on next-generation cancer therapies, and Voyager Acquisition Corp., a special purpose acquisition company listed on Nasdaq, have entered a definitive business combination agreement. The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp..

Xlife Sciences旗下的投资组合公司、专注于下一代癌症疗法的生物制药公司VERAXA Biotech AG，与在纳斯达克上市的特殊目的收购公司Voyager Acquisition Corp.已达成最终的业务合并协议。拟议交易对VERAXA Biotech AG的估值为16.4亿美元，预计总现金收益高达2.53亿美元，由Voyager Acquisition Corp.托管。

VERAXA

维拉克萨

is a Swiss-based biopharmaceutical company advancing a premier drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. The company originates from scientific discoveries made at the European Molecular Biology Laboratory (EMBL), Their proprietary technology, Bi-Targeted Antibody Cytotoxicity platform, enables a highly specific dual-marker approach, allowing the company to accelerate a pipeline of next-generation cancer therapies that have the potential to expand the therapeutic window of current solid tumor standard of care treatments through improved safety and efficacy profiles..

是一家总部位于瑞士的生物制药公司，正在推进一个卓越的药物发现和开发引擎，专注于ADC和其他新型基于抗体的治疗概念。该公司起源于欧洲分子生物学实验室（EMBL）的科学发现。其专有技术——双靶向抗体细胞毒性平台——实现了高度特异性的双标记方法，使公司能够加速推进下一代癌症治疗的研发管线，这些疗法有望通过提升安全性和有效性，扩展当前实体瘤标准治疗方法的治疗窗口。

The company’s pipeline currently comprises nine discovery and development programs at various stages in development, including an active Phase 1 program in leukemia. The Company’s most advanced clinical asset, VX-A901, is developed as a novel therapeutic option for elderly AML (Acute myeloid leukemia) patients. Through a two-fold approach of pursuing both internal innovation and strategic partnerships, the Company anticipates having a robust pipeline by 2029, including three proprietary development programs in the clinic and a growing portfolio of licensed assets..

公司目前的研发管线包括九个处于不同研发阶段的发现和开发项目，其中有一个正在进行的急性髓系白血病一期临床试验项目。公司最先进的临床资产VX-A901，被开发为一种针对老年急性髓系白血病（AML）患者的新治疗选择。通过内部创新与战略合作并行的双重策略，公司预计到2029年将拥有一个强大的研发管线，其中包括三个自主研发的临床开发项目以及不断扩展的授权资产组合。

Post-SPAC valuation for VERAXA anticpated at USD 1.64 billion

VERAXA的SPAC后估值预计为16.4亿美元

VERAXA intends to list as a public company through a strategic merger with

VERAXA 计划通过与一家战略合作伙伴合并的方式成为上市公司，

Voyager Acquisition Corp.

旅行者收购公司

(SPAC), a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector. The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company.

（SPAC），一家开曼群岛的获豁免公司，也是针对医疗保健领域的特殊目的收购公司。拟议的业务合并将创建一家公开上市的、处于临床阶段的生物制药公司。

Upon closing of the transaction, VERAXA will be listed on NASDAQ under the proposed ticker symbol “VERX”. The transaction values VERAXA, which is one of

交易完成后，VERAXA 将在纳斯达克上市，股票代码为 “VERX”。 该交易对 VERAXA 的估值为，它是其中一家

Xlife Sciences

Xlife 科学

’ key portfolio businesses (current stake: ~18%), at approximately USD 1.3 billion (excluding trust funds). VERAXA’s shareholders will receive approximately 130 million shares of the combined company. Assuming a share price of USD 10.00 and no redemptions, the implied pro forma equity value of the combined entity will be approximately USD 1.64 billion.

关键投资组合业务（当前持股：约18%），价值约为13亿美元（不包括信托基金）。VERAXA的股东将获得合并后公司约1.3亿股股份。假设每股价格为10美元且没有赎回，合并后实体的隐含备考股权价值将约为16.4亿美元。

The business combination is expected to close in Q4 2025..

该业务合并预计将于2025年第四季度完成。

Furthermore, following the closing of the Business Combination, VERAXA anticipates access to approximately up to $253 million in cash held in trust by Voyager, prior to the payment of transaction costs of VERAXA and Voyager, and assuming no redemptions by Voyager’s public shareholders. Additionally, VERAXA is actively raising a crossover financing round from existing and new investors to provide VERAXA with sufficient capital for the next two years, not including various potential partnering and co-development opportunities..

此外，在业务合并完成后，VERAXA预计将获得Voyager信托账户中持有的约2.53亿美元现金，此金额在支付VERAXA和Voyager的交易成本之前，并假设Voyager的公众股东不进行赎回。此外，VERAXA正在从现有和新投资者中积极筹集一轮交叉融资，以确保公司未来两年内拥有足够的资本，这还不包括各种潜在的合作与共同开发机会。

(Press release/RAN)

（新闻稿/拉美通讯社）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送